Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Haemonetics (HAE)

Haemonetics: CTO Anila Lingamneni to leave company on November 1, 2024

Neutral Impact 3 of 5 leadership Written later

Haemonetics disclosed that Anila Lingamneni, Executive Vice President and Chief Technology Officer, will leave the company on November 1, 2024. The filing describes her as a named executive officer and gives no successor or reason for the departure.

Key points

  • Anila Lingamneni, Executive Vice President and Chief Technology Officer, will leave on November 1, 2024
  • The departure is listed under Item 5.02 for a named executive officer
  • The filing does not name a successor or give a reason for the departure
  • The 8-K was signed by CEO Christopher A. Simon on September 16, 2024

The filing

CompanyHaemonetics (HAE)
Form8-K, current report
Filed with the SECSep 16, 2024, 4:17 PM ET
Accession number0000313143-24-000056

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.